



European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

London, 14 July 2009
Doc Ref.: EMEA/367714/2009

WORKSHOP

IN VITRO CYTOKINE RELEASE ASSAYS TO PREDICT CYTOKINE RELEASE SYNDROME: THE CURRENT STATE-OF-THE-SCIENCE

The European Medicines Agency (EMA) will hold a workshop to discuss the state-of-the-science of in vitro cytokine release assays on **19 November 2009** at the EMA Offices in London.

The aim of this workshop is to bring together regulatory, academic, and industry scientists to share their experiences with the development and use of cytokine release assays to predict for cytokine release syndrome in humans. Presentations and discussions will be focused on the different types of assays being used, validation studies on assay performance and predictivity, whether and how the assay data could be used to predict human risk, and future needs for assay improvement and new types of assays. Based on these discussions, a list of recommendations will be developed at the meeting and published in a meeting summary.

To express your interest in attending the workshop, please use the attached [registration form](#) and send it back to the EMA (SWP-H@emea.europa.eu) before 23 October 2009. Attendees are invited to submit a poster on cytokine release assays for this meeting (limit of approx. 15 posters). A poster session at lunch and later in the afternoon will be held to share data not presented by the speakers. Please prepare an abstract of your poster (deadline 5 October 2009) and submit it along with the registration form (via e-mail). Posters will be selected based on meeting the aims of this meeting. Each corresponding author of posters submitted will be notified of acceptance by 19 October 2009. One of the posters submitted will be selected for a 15-minute oral presentation. The format of the poster should not exceed the usual format A0 (841 x 1189cm or 33.1 x 46.8 inches).

Please note that approximately 120 places are available for the workshop. Spaces will be allocated on a first-come-first-serve basis.

Further information can be obtained from Monika Croton (E-mail: monika.croton@emea.europa.eu).

The EMA looks forward to welcoming you at the workshop.

Program committee:

Jan Willem van der Laan, National Institute for Public Health and the Environment, The Netherlands, and EMA

Marc Pallardy, Université Paris-Sud, France

Jan Mueller-Berghaus, Paul Erlich Institute, Germany

Stephen Poole, NIBSC, England

Robin Thorpe, NIBSC, England

Huub Schellekens, Utrecht University, The Netherlands

Karin Cederbrant, AstraZeneca

Thomas Kawabata, Pfizer, Inc.

Beatriz Silva Lima, University of Lisbon, INFARMED Portugal

Jean Marc Vidal, EMA